BioSpace News Archive

Replicate Bioscience shared new preclinical data underscoring the strength of Replicate’s srRNA platform and its potential for oncology applications at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented data on WU-NK-101, the company’s lead memory natural killer (NK) cell therapy product, in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida from April 14 – 19, 2023.

Onchilles Pharma, a private biotech company developing novel cancer therapeutics that leverage myeloid biology, presented new preclinical data on N17350, a first-in-class biologic therapeutic inspired by ELANE, a protein found in neutrophils that is part of a newly discovered innate cancer-killing pathway.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”) is pleased to announce that world renowned inflammasome researchers and inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100 from the University of Miami Miller School of Medicine have published a scientific paper in the peer-reviewed journal, Biomaterials.

Exscientia plc (Nasdaq: EXAI) today announced four presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14-19, 2023 in Orlando, FL.

Element Biosciences, Inc. has signed distribution agreements with companies based in Israel, South Korea, Australia, and the United Arab Emirates to bring its AVITI System to more customers around the world.

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology ResearchOnline First of preclinical data for mWTX-330, a systemically delivered Interleukin-12 (IL-12) INDUKINETM molecule.

Indaptus Therapeutics, Inc. announces data presented in a poster at the American Association for Cancer Research annual scientific conference on the Company’s Decoy anti-tumor platform.

Voxeleron, a cloud-based ophthalmic image analysis platform provider, announced today the results of a study demonstrating its Orion platform delivers higher accuracies and reduced variability when compared to original equipment manufacturer (OEM) software from Carl Zeiss Cirrus and Heidelberg Spectralis.

The Insight Partners published latest research report on “Biopharmaceuticals Market Growth Report, Trends, Size, Share, Outlook Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type and Application,” the global size is expected to grow from USD 3,29,966.22 million in 2022 to USD 7,00,873.94 million by 2028; it is expected to grow at a CAGR of 13.4% from 2022 to 2028.